Symbolic methods in control system analysis and design / by Munro, N.

Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes. by Munro, N, Levy, J

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus by Feher M, Greener M, Munro N

Get full text

Does renal function or heart failure diagnosis affect primary care prescribing for sodium-Glucose co-transporter 2 inhibitors in type 2 diabetes? by Hinton, W, Feher, M, Munro, N, de Lusignan, S

How generalizable are cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors? A national database study: study protocol by Hinton, W, Feher, MD, Munro, N, De Lusignan, S

Obstructive sleep apnoea in Type 2 diabetes mellitus: increased risk for overweight as well as obese people included in a national primary care database analysis by Feher, M, Hinton, W, Munro, N, De Lusignan, S

Does real world use of liraglutide match its use in the LEADER cardiovascular outcome trial? study protocol by Hinton, W, Feher, M, Munro, N, De Lusignan, S

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use by McGovern, A, Feher, M, Munro, N, De Lusignan, S

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol) by McGovern, A, Feher, M, Munro, N, De Lusignan, S

Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care by Hinton, W, Feher, M, Munro, N, Joy, M, de Lusignan, S

Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network by Hinton, W, Feher, M, Munro, N, Walker, M, De Lusignan, S

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis by Hinton, W, Feher, MD, Munro, N, Joy, M, de Lusignan, S

Novel diabetes subgroups by Feher, MD, Munro, N, Russell-Jones, D, De Lusignan, S, Khunti, K

Impact of information technology-based interventions for type 2 diabetes mellitus on glycemic control: a systematic review and meta-analysis by Alharbi, N, Alsubki, N, Jones, S, Khunti, K, Munro, N, De Lusignan, S

The association between diabetes, level of glycaemic control and eye infection: cohort database study by Ansari, A, De Lusignan, S, Hinton, W, Munro, N, McGovern, A

Glycemic control is an important modifiable risk factor for uveitis in patients with diabetes: A retrospective cohort study establishing clinical risk and ophthalmic disease burden by Ansari, AS, de Lusignan, S, Hinton, W, Munro, N, Taylor, S, McGovern, A

Hypoglycaemia: making sense of chaotic coding in primary care computerised medical records by Hinton, W, Feher, MD, Munro, N, Kasetty, H, Field, BCT, de Lusignan, S

Ethnic and socioeconomic disparities in type 2 diabetes care: A trend analysis by Hinton, W, McGovern, AP, Calderara, S, Munro, N, Whyte, M, de Lusignan, S

A class comparison of medication persistence in people with type 2 diabetes: A retrospective observational study by McGovern, A, Hinton, W, Calderara, S, Munro, N, Whyte, M, De Lusignan, S

Fenofibrate as a COVID-19 modifying drug: laboratory success versus real-world reality by Feher, M, Joy, M, Munro, N, Hinton, W, Williams, J, de Lusignan, S